Efgartigimod Provides Genuine Benefit For Myasthenia Gravis Disease Overview Efgartigimod, a neonatal Fc receptor inhibitor, has recently received approval for the treatment of myasthenia gravis (MG). This retrospective cohort study systematically evaluated the short- and long-term efficacy of efgartigimod in patients with refractory MG. Sixteen patients with autoimmune acetylcholine receptor MG, who
Tag: myasthenia gravis
Myasthenia Gravis Therapeutic Benefits Of Monotherapy With Tacrolimus
Myasthenia Gravis Therapeutic Benefits Of Monotherapy With Tacrolimus Overview In the management of mild to moderate myasthenia gravis (MG), the utilization of tacrolimus is typically reserved for cases that do not respond to glucocorticoids. This study sought to assess the potential advantages of mono-tacrolimus over mono-glucocorticoids in treating MG patients. The primary endpoint
